Clinical Findings Confirm the Scientific Basis and Safety of the First-of-Its-Kind Medical Food That Delivers an 85% Improvement in Bone Density

BOSTON, Feb. 20, 2026 — Sōlaria Biō, a biotechnology company pioneering natural solutions for healthy aging, recently published results from a new open-label, randomized clinical study in , evaluating the gut delivery, viability and persistence of two synbiotic medical foods: Bōndia (tested as SBD111), the company’s clinically studied bone health medical food, and SBD121, an investigational synbiotic formulation. The study used a rigorous, strain-specific clinical approach to check if the food-derived microbes in both products effectively reach the human gut and act as expected during and after use. This evidence adds to the body of research showing that Bōndia has the right microbial strains to deliver maximum bone health benefits to consumers.

Over half of women over 50 are affected by osteopenia or osteoporosis—conditions driven by declining estrogen, inflammation, and changes in the gut microbiome—making the need for safe, effective, long-term gut-targeted interventions clearer than ever. Bōndia meets this need as the first-in-class, high-potency synbiotic medical food shown to boost bone density by 85% in women with osteopenia.

“This study answers a fundamental question in microbiome science: Do these strains actually reach the gut, stay viable, and behave as designed?” said Catherine Balsam-Schwaber, CEO of Sōlaria Biō. “Using strain-level tools, we generated high-quality clinical evidence that supports both the safety and scientific integrity of our medical food formulations.”

Key Findings

• Rapidly detectable and viable in the human gut: The microbial strains in Bōndia were quickly identified during consumption and confirmed to be alive, demonstrating effective delivery through the gastrointestinal tract—an essential requirement for biological activity.
• Persistent, consistent, and safely washed out: Study participants showed reliable strain detection across individuals (83–100%) with short-term persistence during supplementation, followed by natural elimination after stopping use. Importantly, this did not disrupt overall gut microbiome diversity or function, supporting both safety and predictability.
• Rigorous clinical validation of Bōndia as a bone health medical food: Through strain-specific quantitative PCR, metagenomic sequencing, and culture-based recovery, the study provides strong clinical validation of Bōndia’s formula and reinforces prior efficacy data supporting its role as a bone health medical food.

Conducted with healthy adults, the study joins Sōlaria Biō’s growing body of mechanistic and clinical research on Bōndia previously published in and .

Sōlaria Biō continues to form impactful partnerships with brands and innovators that share its mission to pioneer natural, effective health solutions, including:

• Joining the 2026 winter cohort of the Accelerator alongside a dynamic group of innovators transforming the future of longevity and wellness.
• Partnering with DexaFit to make clinical-grade bone density testing more accessible to women nationwide. By expanding access to gold-standard DXA scans, the Sōlaria Biō community can establish an early baseline and monitor changes over time—a critical step in proactive skeletal health. This collaboration helps turn findings into measurable action, empowering women to objectively track, protect, and optimize their long-term bone health.
• Partnering with 51&, a member-driven network that unites women’s voices, resources, and civic action to rebuild a health system never designed for them.

Bōndia is now available for direct order at and through partner healthcare providers.

About Sōlaria Biō
Sōlaria Biō is a Waltham, MA-based biotechnology company dedicated to advancing the future of aging and improving collective health outcomes in measurable ways. The company has built a diverse, best-in-class catalog of bacterial and fungal strains isolated from fresh fruits and vegetables, a genome database, and an AI-powered computational platform to mine these strains for medical food development. Sōlaria Biō integrates the highest scientific rigor into every step of its process, validating products in robust randomized, placebo-controlled clinical food trials to create novel solutions for managing inflammatory diseases. To learn more, visit: .

Press Contacts
Patricia Rappaport
 
Civic on behalf of Sōlaria Biō

Chloe Lauter
 
Civic on behalf of Sōlaria Biō

SOURCE Sōlaria Biō